{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.2","value":"317"},{"groupId":"OG001","spread":"34.2","value":"314"},{"groupId":"OG002","spread":"35.0","value":"433"},{"groupId":"OG003","spread":"34.3","value":"889"},{"groupId":"OG004","spread":"33.6","value":"901"},{"groupId":"OG005","spread":"38.0","value":"1328"},{"groupId":"OG006","spread":"20.4","value":"2017"},{"groupId":"OG007","spread":"1.73","value":"1990"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"408"},{"groupId":"OG009","spread":"31.3","value":"389"},{"groupId":"OG010","spread":"46.2","value":"594"},{"groupId":"OG011","spread":"17.1","value":"750"},{"groupId":"OG012","spread":"75.0","value":"954"},{"groupId":"OG013","spread":"150","value":"1937"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.2","value":"411"},{"groupId":"OG001","spread":"35.7","value":"377"},{"groupId":"OG002","spread":"31.5","value":"552"},{"groupId":"OG003","spread":"23.7","value":"1077"},{"groupId":"OG004","spread":"28.6","value":"1270"},{"groupId":"OG005","spread":"32.5","value":"1740"},{"groupId":"OG006","spread":"25.6","value":"2442"},{"groupId":"OG007","spread":"18.2","value":"2228"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"488"},{"groupId":"OG009","spread":"25.8","value":"507"},{"groupId":"OG010","spread":"39.2","value":"719"},{"groupId":"OG011","spread":"18.8","value":"946"},{"groupId":"OG012","spread":"76.2","value":"1209"},{"groupId":"OG013","spread":"126","value":"2836"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"title":"Total Antibody Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG004","spread":"28.3","value":"0.0120"},{"groupId":"OG005","spread":"35.8","value":"0.0170"},{"groupId":"OG006","spread":"21.8","value":"0.0140"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG007","spread":"NA","value":"0.0140"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG010","spread":"NA","value":"0.0110"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG011","spread":"NA","value":"0.0120"},{"groupId":"OG012","spread":"5.97","value":"0.0130"},{"groupId":"OG013","spread":"185","value":"0.0250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"1"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.8","value":"405"},{"groupId":"OG001","spread":"109","value":"448"},{"groupId":"OG002","spread":"28.6","value":"497"},{"groupId":"OG003","spread":"78.3","value":"999"},{"groupId":"OG004","spread":"34.5","value":"939"},{"groupId":"OG005","spread":"43.7","value":"1527"},{"groupId":"OG006","spread":"11.1","value":"2150"},{"groupId":"OG007","spread":"13.2","value":"2208"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"1270"},{"groupId":"OG009","spread":"43.0","value":"407"},{"groupId":"OG010","spread":"38.5","value":"603"},{"groupId":"OG011","spread":"82.7","value":"862"},{"groupId":"OG012","spread":"125","value":"1089"},{"groupId":"OG013","spread":"46.4","value":"1297"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Conjugated Antibody Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.60","value":"490"},{"groupId":"OG001","spread":"122","value":"560"},{"groupId":"OG002","spread":"24.7","value":"592"},{"groupId":"OG003","spread":"62.3","value":"1420"},{"groupId":"OG004","spread":"22.9","value":"1354"},{"groupId":"OG005","spread":"35.1","value":"1797"},{"groupId":"OG006","spread":"2.67","value":"2624"},{"groupId":"OG007","spread":"7.98","value":"2907"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG008","spread":"NA","value":"1660"},{"groupId":"OG009","spread":"44.6","value":"463"},{"groupId":"OG010","spread":"29.7","value":"745"},{"groupId":"OG011","spread":"71.1","value":"1149"},{"groupId":"OG012","spread":"128","value":"1355"},{"groupId":"OG013","spread":"24.9","value":"1690"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"7"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"3"},{"groupId":"OG013","value":"3"}],"units":"Participants"}],"title":"Total Antibody Cycle 2"},{"categories":[{"measurements":[{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG003","spread":"NA","value":"0.0130"},{"groupId":"OG004","spread":"3.82","value":"0.0130"},{"groupId":"OG005","spread":"3.23","value":"0.0110"},{"groupId":"OG006","spread":"8.29","value":"0.0170"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG010","spread":"NA","value":"0.0100"},{"groupId":"OG011","spread":"26.4","value":"0.0100"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG012","spread":"NA","value":"0.0190"},{"comment":"Data not available due to insufficient number of observations to determine geometric coefficient of variation.","groupId":"OG013","spread":"NA","value":"0.0120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"2"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"}],"units":"Participants"}],"title":"Unconjugated SG3199 Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"10"},{"groupId":"OG011","value":"9"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"6"}],"units":"Participants"}],"description":"The PK profile included determination of Cmax in serum Total antibody, PBD-conjugated Antibody and Unconjugated Warhead SG3199. For participants treated with ADCT-301 in combination with pembrolizumab, the collection of PK data was stopped upon consultation with the Sponsor if ADCT-301 administration was discontinued and pembrolizumab continues.\n\nUpon consultation with the Sponsor, no further PK samples were collected, ADCT-301 was permanently discontinued and pembrolizumab continues as single agent.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"ADCT-301 Monotherapy 20 µg/kg"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"ADCT-301 Monotherapy 30 µg/kg"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"ADCT-301 Monotherapy 45 µg/kg"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"ADCT-301 Monotherapy 60 µg/kg"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"ADCT-301 Monotherapy 80 µg/kg"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"ADCT-301 Monotherapy 100 µg/kg"},{"description":"Participants received 125 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG006","title":"ADCT-301 Monotherapy 125 µg/kg"},{"description":"Participants received 150 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle.","id":"OG007","title":"ADCT-301 Monotherapy 150 µg/kg"},{"description":"Participants received 20 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG008","title":"ADCT-301 Combination Therapy 20 µg/kg + Pemb"},{"description":"Participants received 30 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG009","title":"ADCT-301 Combination Therapy 30 µg/kg + Pemb"},{"description":"Participants received 45 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG010","title":"ADCT-301 Combination Therapy 45 µg/kg + Pemb"},{"description":"Participants received 60 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG011","title":"ADCT-301 Combination Therapy 60 µg/kg + Pemb"},{"description":"Participants received 80 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG012","title":"ADCT-301 Combination Therapy 80 µg/kg + Pemb"},{"description":"Participants received 100 µg/kg ADCT-301 Q3W, IV infusion on Day 1 of each 21-day cycle and Pembrolizumab was administered as a 30 minute IV infusion at a fixed dose of 200 mg (starting 1 hour after the end of the ADCT-301 infusion).","id":"OG013","title":"ADCT-301 Combination Therapy 100 µg/kg + Pemb"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Analysis Set: The PK analysis set consisted of all participants who received study drug and had at least 1 pre-C1D1 and 1 post-dose valid assessment.\n\nThe overall number of participants analyzed represents the number of participants with available PK data at any timepoint.\n\nIncludes participants with available data at each timepoint.","reportingStatus":"POSTED","timeFrame":"C1D1, from Pre-dose to 4 hr, 96 hr, 168 hr and 336 hr post dose; C2D1, from Pre-dose to 4 hr, 48 hr, 96 hr, 168 hr and 336 hr post dose","title":"Maximum Concentration (Cmax) of ADCT-301 in Serum Total Antibody, PBD-conjugated Antibody and Unconjugated Warhead SG3199","type":"SECONDARY","unitOfMeasure":"µg/L"}